Deshen Wang

GI medical oncologist at Sun Yat-sen University Cancer Center, China

[Deshen Wang @DeshenW]

A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases - De-Shen Wang, 2026 https://t.co/tiyRSne73A

[Anirban Maitra @Aiims1742]

The final results from @ElicioTx AMPLIFY trial are in @NatureMedicine reinforcing what has been seen with other platforms - a robust T cell response to tumor antigens post-vaccine is associated with delayed #PancreaticCancer recurrence after surgery.
https://t.co/jyfwaW7z1H

[Deshen Wang @DeshenW]

Safety and Efficacy of Adjuvant FOLFOX/FOLFIRI with versus without Hepatic Arterial Infusion of Floxuridine in Patients Following Colorectal Cancer Liver Metastasectomy (HARVEST trial): A Randomized Controlled Trial - European Journal of Cancer https://t.co/BiEf0brXgW

[Deshen Wang @DeshenW]

Read our latest article "Percutaneous Hepatic Artery Infusion Chemotherapy with Oxaliplatin and Fluoropyrimidines in Treatment-Resistant Colorectal Cancer Patients with Unresectable Liver Metastases: A Retrospective Cohort Study" - HPB https://t.co/z8JNCWZ9X1

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

New @TheLancet - Adam et al - Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet trial)

https://t.co/05kYRbhSBK

#CRCSM #LiverTwitter

[Deshen Wang @DeshenW]

ALK fusions in colorectal cancer: another tumor-agnostic target? | #npj Precision Oncology @Nature_NPJ https://t.co/w52N1PFqLR

[PLOS Medicine @PLOSMedicine]

De-Shen Wang and colleagues evaluate the efficacy and safety of cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as a conversion regimen in CRC patients with initially unresectable colorectal liver metastases. #clinicaltrial #colorectalcancer
🔬: https://t.co/LDd9mjfNkn

[Deshen Wang @DeshenW]

The TRICE trial was just published. Thanks to the study team, all patients, and family. #CRLM #PLOSMedicine: Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-t ... https://t.co/YhVtTrbZD7

[Deshen Wang @DeshenW]

Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases - Zhi-Gang Chen, ..., De-Shen Wang, Yu-Hong Li, 2024 #colorectal #liver #metastasis #ctDNA @TAMedOncol https://t.co/Rj49GkDQSq

[Arndt Vogel @ArndtVogel]

🔥of the press: Association of RNF43 Genetic Alterations With BRAFV600E & MSIhigh in Colorectal Cancer
@JCOPO_ASCO
https://t.co/0vAthlNe57
👉Interesting associations of RNF43 with BRAF, TMB & MSI
🧐Potential impact on anti-EGFR and -BRAF 🎯💊
@myESMO

[Deshen Wang @DeshenW]

Glad to see our paper published at @TAMedOncol. RNF43 mutations in NTD and the R117fs variant correlate with a poorer prognosis in CRC. https://t.co/JdemXYRZpe
Clinical and molecular characteristics of RNF43 mutations as promising prognostic biomarkers in colorectal cancer.

[Deshen Wang @DeshenW]

Our study was recently published.
Monitoring tumour resistance to the BRAF inhibitor combination regimen... https://t.co/xD0Zax2OCJ

[The Lancet Oncology @TheLancetOncol]

New Research: Recurrence-free #survival versus overall survival as a primary #endpoint for studies of resected #colorectal #liver #metastasis: a retrospective study and meta-analysis https://t.co/RASj5F6JAX

[Deshen Wang @DeshenW]

Read our latest article “Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma”, published with @SpringerNature
in @Gastric Cancer https://t.co/52O1SSSNQg

[Deshen Wang @DeshenW]

Our paper is out! Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation https://t.co/hlQMTWfF2K

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC short report: Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring POLE exonuclease domain mutation https://t.co/GoV4JGWjaI

[Deshen Wang @DeshenW]

Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer https://t.co/0yL1gTadfK

[Deshen Wang @DeshenW]

Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil for Nasopharyngeal Carcinoma https://t.co/EoZvYRxFK7 via @JAMAOnc part of @JAMANetwork

[Deshen Wang @DeshenW]

Read my latest #research on #CRLM, published with
@SpringerNature in @AnnSurgOncol https://t.co/vEglqOUl9S

[Deshen Wang @DeshenW]

Capecitabine Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma https://t.co/867ouvzgF9 via @JAMAOnc part of @JAMANetwork